Edition:
United Kingdom

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

5,000JPY
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
¥5,000
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
148,933
52-wk High
¥5,120
52-wk Low
¥2,133

Select another date:

Thu, Oct 26 2017

BRIEF-JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

* Says it will initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

BRIEF-NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

* Says it and NanoCarrier Co., Ltd conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

BRIEF-JCR Pharmaceuticals submits application for marketing approval of JR-051 for Fabry disease

* Says it has submitted an application for marketing approval on JR-051 (recombinant alpha-galactosidase A), an enzyme replacement therapy (ERT) for Fabry disease to Ministry of Health, Labour and Welfare

BRIEF-JCR Pharmaceuticals completes share repurchase through ToSTNeT-3

* Says it completed repurchase of 854,100 shares of its common stock, for 2.62 billion yen in total, through ToSTNeT-3, on Sept. 22

BRIEF- JCR Pharmaceuticals to repurchase shares

* Says it will repurchase up to 940,000 shares of its common stock, representing 2.7 percent of outstanding, on Sept. 22

BRIEF- JCR Pharmaceuticals announces shareholding structure change

* Says its top shareholder GLAXO GROUP LIMITED will cut voting power in the company to 0 percent from 25.2 percent

BRIEF- JCR Pharmaceuticals announces business and capital alliance with Medipal Holdings

* Says it signed a business and capital alliance with Medipal Holdings Corp

BRIEF- JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin

* Says it entered into co-development and license agreement with Teijin Ltd, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18

Select another date: